Completed PHASE3 INTERVENTIONAL 2-arm NCT03317574

MEDITOXIN® in Treatment of Crow's Feet Line

A Randomized, Double-blind, Active Drug Controlled, Multi-center, Phase Ⅰ/Ⅲ Study to Determine the Efficacy and Safety of Meditoxin® in Treatment of Crow's Feet Line

Sponsor: Medy-Tox

Conditions Crow's Feet Lines

Interventions botulinum toxin type A

Updated 6 times since 2017 Last updated: Mar 25, 2019 Started: Aug 17, 2017 Primary completion: Dec 1, 2017 Completion: May 14, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Crow's Feet Lines and is currently completed. Medy-Tox leads this study, which shows 6 recorded versions since 2017 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Apr 2019 — Jan 2021 [monthly]

Completed PHASE3

Status: Recruiting → Completed

▶ Show 1 earlier version

Nov 2017 — Apr 2019 [monthly]

Recruiting PHASE3

First recorded

Aug 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Medy-Tox

Data source: Medy-Tox

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Gyeonggi-do, South Korea